LAS VEGAS, May 28, 2013 /PRNewswire/ -- PharmaRoth
Labs, Inc. (OTC Pink: ROTH) the exclusive producer, marketer &
distributor of Sucanon®, an oral Type-II Diabetes
treatment, announced today that it has entered into a
definitive agreement with Marcas de Renombre, S.A de C.V. granting
Marcas exclusive rights for the commercialization and distribution
of Sucanon® in Mexico.
The agreement is for 50 years with annual sales increases
conditional for continuance of exclusivity, with the first shipment
anticipated in June.
"We are very pleased to announce this agreement with Marcas de
Renombre" said Luis Lopez, CEO of
PharmaRoth. "We believe we have found a partner that is uniquely
positioned to ensure market access and the commercial success of
Sucanon®. This agreement is a major milestone for
PharmaRoth, and a clear recognition of the demand
Sucanon® brings." MDR's marketing strategy is a direct
to Consumer Company with massive advertising through most media
channels.
About
Sucanon®
Sucanon® is approved as an
OTC treatment for Type-II diabetes by regulatory authorities in
Mexico, containing natural
ingredient. It is one of only three approved drugs in the
multi-billion dollar market for a class of diabetic medications
called "insulin sensitizers". Pre-clinical and clinical
studies conducted ex-US have shown that Sucanon® and
other insulin sensitizers lower a patient's blood sugar by
increasing the muscle, fat and liver's sensitivity to the body's
own naturally produced insulin.
For further information regarding Sucanon®, please
visit PharmaRoth Labs, Inc. website at http://pharmaroth.com/
About PharmaRoth Labs Inc.
PharmaRoth Labs, Inc. (OTCPink: ROTH) is focused on diabetes
prevention and treatments. The Company holds the intellectual
property and all exclusive world-wide rights related to the
production, marketing, and distribution of Sucanon®, an
oral treatment for Type-II diabetes. Sucanon® is a
member of a class of diabetic medications called insulin
sensitizers. Insulin sensitizers lower blood sugar by
increasing the muscle, fat and liver's sensitivity to
insulin. Insulin sensitizers are blood sugar normalizing or
euglycemic drugs that help return the blood sugar to the normal
range without the risk of low blood sugars. PharmaRoth's
strategy is to increase awareness, acceptance, and distribution of
Sucanon® globally.
About Marcas de Renombre S.A. de
C.V.
Marcas de Renombre is
established as company that develops and distributes several
brands in different areas as skin cosmetics, personal care,
and OTC. With more than 1,000 employees and growing annual sales,
it is one of the largest advertisers in the Mexican Market.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are based on the current plans and
expectations of management and are subject to a number of
uncertainties and risks that could significantly affect the
company's current plans and expectations, as well as future results
of operations and financial condition. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact and Inquiries for Investor Relations:
Michael Irving
Paramount Advisors, LLC
407-878-5462
mike@parvise.com
SOURCE PharmaRoth Labs, Inc.